Invest in Future Medicines Investment Pitch Deck Your chance to Invest in Future Medicines

Cannabis a growing trend Around the world Cannabis is being given serious considerations for its possible use in the medicine industry. Isreal now runs a fully functioning medical research facility specializing in cannabis plant materials for medical supply. Canada, the USA, and Uruguay are among the world's leaders in allowing the supply of cannabis product for people suffering from ailments in which the use of cannabis is supported. Green Pharma BioTech NZ proposes to take this growth one step further by producing pure organic cannabis strains that are patentable. 2

Patentable Product Green Pharma BioTech will produce in its first year a patentable strain of cannabis plant and in the following 3 years produce 2 more such patents. The benefits of owning patents for plant strains allows us to approach pharmaceuticals with a product that is guaranteed as chemical free proven THC % levels proven CBD % levels and suitable for children's medicine 3

Market Reach Supply product to pharmaceuticals internationally Supply product to dispensaries internationally Supply seeds to seed banks Supply product to universities and medical research facilities both internationally and locally And supply local doctors with product for test cases 4

Index Vision Momentum, Traction, Expertise Market Opportunity Problem & Current Solutions Product & Service Business Model Market Approach & Strategy Team & Key Stakeholders Financials Competition Investment 5

Company Vision “We supply Kiwi Buds for Global Happiness” Our tongue in cheek motto is easily understood by all and reflects our focus on health and family happiness: “We supply Kiwi Buds for Global Happiness” 6

Traction August 2014: Our CEO penned the NZ Govt. Policy for Cannabis Health Law Reforms. Core team were assembled. Expert grower signed on. September 2014: Farm 17 years registered as organic acquired. Lawyer signed on. Research on plant strains and patentable plant varieties started. New buildings for the farm researched. October 2014: Our CEO and Managing Director work full time for company. Company registration started. Funding sought. 7

Market Opportunity Our projected market is a niche market supplying cannabis for medicinal use to; Pharmaceuticals Doctors Labs Dispensaries Drug Stores/Chemists/Pharamcies and other BioTechs And we want to achieve full global coverage and product placement. 8

The Problem Current Solutions Our Solution Lack of scientifically proven reputably produced medical cannabis strains for the global market. Current Solutions Other than a few universities and small private enterprises Israel is the world leader and the only reputable supplier of medical cannabis products. Our Solution To move into the global market with a far superior product and one that will be adopted by leading pharmaceuticals. 9

Product / Service As a global supplier Green Pharma BioTech Ltd will supply its product to other companies and we will control that release through approved sellers and distributors only. We aim to produce only high end product that will be sold at premium prices at dispensaries, however for pharmaceuticals we aim to be a cost effective solution for bulk supply of the product. 10

Revenue Model Our Model: Low company costs, high priced end product, lead supplier to a demanding emerging market. Although as an investor you are expecting a long winded detailed “revenue model” and we would love to provide if such existed for this type of industry. We are simply growing and breeding plants for supply. Revenue is based on sales from seeds and plant products to buyers of the medicine cannabis arena. 11

Marketing & Growth Strategy Our product by way of much research and development will be the only patented product available for supply to the market. It will also be the only proven 100% Organically Grown product safe for inclusion in both child and adult medicines. We plan to and with great confidence hope to monopolize the market because it is still very much a virgin market. 12

Team Grant Keinzley, CEO: ex Politician and Humanitarian. Rob Stewart, Managing Director: Public Servant and Manager Rosie Purchas, Director: Human Rights Law Activist and Lawyer Tipene Butter Master Grower: Horticulturalist and experienced Medical Cannabis plant breeder. 13

Financials Year 1 $661,200 $400,000 5~10% Year 2 $470,800 $1,600,000 From start up to the end of the third year most of the company's activities are growing, plant breeding, and patent plant strain development. From the first year sales revenue comes from supplying seeds to global seed banks. It is expected that by the end of the third year that full product supply to pharmaceuticals will have begun and from this point on the company moves into a virgin billion dollar industry. Our conservative & safe 3 year financial plan (we expect to make a lot more than this). Setup, Running Costs, & Overheads Sales Profits Market Penetration Year 1 $661,200 $400,000 5~10% Year 2 $470,800 $1,600,000 30% Year 3 $1,200,000 45% 14

Competition In the global marketplace there is only one serious competitor; that being the Medical Cannabis Research Center in Isreal. Our market advantage is our focus on producing 100% organic product and that our product is precise in its engineering. Our plant strains' core elements THC & CBD are incrementally measured as; .1% CBD .2% CBD versus present medicinal use supplies measuring in at; 1.0% CBD 2.0% CBD This makes our product superior and more suitable for medical applications. 15

Investment We are seeking NZ$3,000,000 equaling 25% o the company as seed capital to implement the full launch of the company. The seed capital covers 5 years of the company's running costs, staff costs, infrastructure costs, and some buildings constructed on the property. The return on investment will be in dividends based on profit and share value. We offer all interested investors a personalised investment portfolio. $3million is a lot but if you have $30,000 you can still take a piece of the pie, Give us a call. 16

Final Note & Thanks Because of the nature of this enterprise; growing and breeding plants for patenting, simply said “its not rocket science” Why we will dominate the market is because we will be distributing proven quality assured medical use product that with the employ of an international distribution and sales company will flood the market and make our brand the only brand. We at Green Pharma BioTech thank you for your consideration and time and look forward to doing business with you. Grant Keinzley, CEO of Green Pharma BioTech 17